Fitzpatrick Tiffany, Yamoah Peter, Summerby-Murray David, Cowan Juthaporn, Sadarangani Manish, Wright Alissa, Belga Sara, Constantinescu Cora, Carignan Alex, McConnell Athena, Top Karina A
Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada; Canadian Center for Vaccinology, IWK Health and Dalhousie University; Halifax, NS, Canada; Public Health Ontario; Toronto, ON, Canada.
Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Vaccine. 2025 Jun 20;59:127254. doi: 10.1016/j.vaccine.2025.127254. Epub 2025 May 20.
Neurological adverse events have been reported rarely following COVID-19 vaccination. This study describes the characteristics of adolescents and adults assessed in the Canadian Special Immunization Clinic (SIC) Network for neurological adverse events following immunization (AEFIs) and outcomes of revaccination. Among 60 participants enrolled from January 2021 to February 2023, paresthesia/anesthesia was the most common diagnosis (15/60; 25.0 %), followed by Bell's Palsy (6/60; 10.0 %). Twenty-eight percent (17/60) of participants were hospitalized for their AEFI. Revaccination was recommended to 32/46 (69.6 %) participants due for subsequent doses when assessed in the SIC. Twenty-three participants were revaccinated and 4/23 (17.4 %) had recurrent symptoms of the AEFI; three were milder than the first event and none required hospitalization. Revaccination was generally safe in selected patients after a neurological AEFI. Expert assessment of patients with neurological AEFIs may help to support further vaccination.
接种新冠疫苗后很少有神经不良事件的报告。本研究描述了在加拿大特殊免疫诊所（SIC）网络中评估的青少年和成人接种疫苗后神经不良事件（AEFI）的特征以及再次接种的结果。在2021年1月至2023年2月登记的60名参与者中，感觉异常/麻木是最常见的诊断（15/60；25.0%），其次是贝尔麻痹（6/60；10.0%）。28%（17/60）的参与者因AEFI住院。在SIC评估时，46名应接种后续剂量疫苗的参与者中有32名（69.6%）被建议再次接种。23名参与者进行了再次接种，其中4/23（17.4%）出现了AEFI的复发症状；3例症状比首次事件轻，均无需住院。在发生神经AEFI后，对选定患者进行再次接种总体上是安全的。对神经AEFI患者进行专家评估可能有助于支持进一步接种疫苗。
